The Federal Trade Commission, along with California and Utah consumer protection agencies, sued Hims & Hers Health, Inc. for allegedly charging customers immediately after intake forms without clear disclosure and making subscription cancellations difficult. The FTC also claims the company misled consumers about privacy by sharing health data with third parties like Meta and Snap. Following the lawsuit announcement, Hims & Hers stock fell 14.73% to $25.00 per share. Investors and those affected are encouraged to contact Kaplan Fox & Kilsheimer LLP, which is investigating potential securities violations related to these allegations.
Hims & Hers Health reported disappointing Q3 results with subscriber numbers falling quarter-over-quarter and gross margin hitting a new low. The company also gave a weak outlook for Q4 and fiscal year 2026. However, much of this underperformance was...
The global telehealth market, valued at $77.4 billion in 2025, is projected to expand to $187.5 billion by 2033, driven by increasing patient demand for virtual care and advances in AI, remote monitoring, and wearable health devices. Companies like R...
Hims & Hers Health reported Q3 2026 revenue of $890.3 million, slightly missing analyst consensus by $2.5 million but meeting midpoint guidance. The company strategically reduced marketing spend to 28% of revenue, down from 39% the previous year, in ...
Hims & Hers reported a surprise Q3 loss and cut its full-year profit outlook, causing its stock to drop 18%. Despite 48.6% revenue growth, the company missed revenue estimates and faced margin pressure due to lower-margin weight-loss products and int...
Hims & Hers stock dropped 25.67% in a week following its deal with Eli Lilly to expand access to weight-loss drugs, despite Lilly's modest share gains. The decline reflects challenges from Hims' shift to branded GLP-1 drugs, including a drop in gross...
